HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

nateglinide (Starlix)

Subscribe to New Research on nateglinide

considered one of the glinides, an imprecise grouping; structure in first source; RN refers to (trans,D-Phe)-isomer

Also Known As:

Starlix; A 4166; A-4166; AY 4166; AY-4166; DJN 608; Fastic; IPCCPA; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; Novartis brand of nateglinide; Starsis; nate-glinide; nateglinide, (D-Phe)-isomer; nateglinide, (cis,D-Phe)-isomer; senaglinide; D-phenylalanine, N-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-

Networked: 144 relevant articles (25 outcomes, 42 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Califf, Robert M: 8 articles (03/2015 - 10/2008)
2.	Haffner, Steven M: 7 articles (11/2013 - 10/2008)
3.	Holman, Rury R: 6 articles (11/2013 - 10/2008)
4.	Kawamori, Ryuzo: 6 articles (06/2012 - 11/2002)
5.	Watada, Hirotaka: 5 articles (09/2015 - 08/2004)
6.	McMurray, John J V: 5 articles (03/2015 - 04/2010)
7.	Tognoni, Gianni: 5 articles (11/2013 - 04/2010)
8.	Bethel, M Angelyn: 5 articles (11/2013 - 10/2008)
9.	Hirose, Takahisa: 4 articles (09/2015 - 12/2002)
10.	Sun, Jie-Lena: 4 articles (03/2015 - 03/2013)

Related Diseases

1.	Hyperglycemia 09/01/2002 - "In sum, nateglinide is a safe and effective therapeutic option for treatment of patients with mild to moderate fasting hyperglycemia." 12/01/2002 - "Nateglinide was safe and effective in reducing postprandial hyperglycemia in subjects with IGT. " 05/01/2014 - "However, nateglinide pretreated i.c.v. did not affect the KA-induced neuronal cell death and hyperglycemia. " 06/01/2005 - "Since postprandial hyperglycemia could be well treated by nateglinide, we examined the background factors of type 2 diabetic patients to determine the optimal indication for nateglinide. " 09/01/2002 - "Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia."
2.	Insulin Resistance 03/01/2006 - "Beneficial effects of nateglinide on insulin resistance in type 2 diabetes." 03/01/2011 - "Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in zucker Fatty rats by suppressing advanced glycation end product receptor axis." 03/01/2006 - "Nateglinide ameliorates insulin resistance as well as insulin secretory defects in type 2 diabetic patients." 03/01/2006 - "The aim of this study is to evaluate the effect of nateglinide on insulin resistance as well as insulin secretory defects in type 2 diabetic patients. " 03/01/2005 - "The aim of this study was to investigate the influence of changes in insulin resistance and early insulin secretion on the insulin secretagogic effects of nateglinide. "
3.	Type 2 Diabetes Mellitus (MODY) 07/01/2003 - "Results of STOP-NIDDM trial suggest that nateglinide, which attenuates post-prandial glycemic surge in type 2 diabetes, may also be helpful for the protection against cardiovascular events. " 02/01/2005 - "Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography." 06/01/2003 - "Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study." 03/01/2013 - "Nateglinide is commonly used in the treatment of patients with type 2 diabetes mellitus. " 01/01/2010 - "Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus."
4.	Hypoglycemia (Reactive Hypoglycemia) 11/01/2005 - "This study was conducted to identify the nature of any adverse effects associated with nateglinide and to evaluate its clinical efficacy in patients with type 2 diabetes, with particular attention to hypoglycemia. " 12/01/2013 - "One of the dangerous side effects of nateglinide administration is rapid hypoglycemia, a condition that needs to be monitored carefully to prevent unnecessary fatalities. " 04/22/2010 - "Nateglinide did, however, increase the risk of hypoglycemia. " 11/01/2005 - "Severe hypoglycemia was recognized in only 1 case of diabetes complicated by serious renal dysfunction, for which nateglinide has been contraindicated in Japan. " 01/01/2005 - "Hypoglycemia following a nateglinide overdose in a suicide attempt."
5.	Prediabetic State (Prediabetes) 12/01/2014 - "In prediabetes, several well-designed preventive trials have shown that lifestyle and pharmacologic interventions such as metformin, thiazolidinediones (TZD), acarbose and, nateglinide and orlistat, are effective in reducing diabetes development. " 11/01/2005 - "Several drugs having different mechanisms of action, such as metformin, glitazones, acarbose, orlistat, nateglinide, glicazide, angiotensin-converting enzymes, angiotensin receptor blockers have been found to be effective in prediabetes to improve the glycaemic status, though they are still not recommended by any professional organisation."

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Metformin (Glucophage)
3.	Acarbose
4.	voglibose
5.	Glucose (Dextrose)
6.	Glyburide (Glibenclamide)
7.	Blood Glucose (Blood Sugar)
8.	repaglinide (Prandin)
9.	Thiazolidinediones
10.	orlistat (Xenical)

Related Therapies and Procedures

1.	Exercise Therapy (Therapy, Exercise)
2.	Transplantation (Transplant Recipients)
3.	Oral Administration